Deep-pocketed investors have adopted a bearish approach towards Eli Lilly LLY, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in LLY usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 21 extraordinary options activities for Eli Lilly. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 23% leaning bullish and 66% bearish. Among these notable options, 4 are puts, totaling $432,164, and 17 are calls, amounting to $1,185,751.
Predicted Price Range
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $460.0 to $1000.0 for Eli Lilly during the past quarter.
Insights into Volume & Open Interest
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Eli Lilly's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Eli Lilly's whale trades within a strike price range from $460.0 to $1000.0 in the last 30 days.
Eli Lilly Call and Put Volume: 30-Day Overview
Noteworthy Options Activity:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LLY | CALL | TRADE | BEARISH | 02/21/25 | $50.0 | $48.8 | $48.8 | $780.00 | $244.0K | 1.4K | 51 |
| LLY | PUT | SWEEP | BULLISH | 01/31/25 | $9.75 | $8.7 | $8.7 | $815.00 | $185.7K | 5 | 208 |
| LLY | CALL | TRADE | BEARISH | 12/18/26 | $173.2 | $170.2 | $170.2 | $800.00 | $170.2K | 163 | 10 |
| LLY | CALL | TRADE | BULLISH | 02/21/25 | $153.9 | $152.3 | $153.9 | $660.00 | $153.9K | 51 | 10 |
| LLY | PUT | TRADE | BEARISH | 09/19/25 | $40.55 | $38.3 | $40.55 | $720.00 | $101.3K | 389 | 25 |
About Eli Lilly
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
After a thorough review of the options trading surrounding Eli Lilly, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
Current Position of Eli Lilly
- With a volume of 339,987, the price of LLY is down -0.05% at $807.75.
- RSI indicators hint that the underlying stock may be approaching overbought.
- Next earnings are expected to be released in 9 days.
Professional Analyst Ratings for Eli Lilly
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $1080.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access. * Maintaining their stance, an analyst from Wells Fargo continues to hold a Overweight rating for Eli Lilly, targeting a price of $970. * Consistent in their evaluation, an analyst from Citigroup keeps a Buy rating on Eli Lilly with a target price of $1190.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Eli Lilly options trades with real-time alerts from Benzinga Pro.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
